TEM — Recent News Coverage
All news mentioning TEM in ESEN's AI-graded feed
News stories with TEM as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on TEM. See /coverage/TEM for the 30-day aggregate.
FINANCE.YAHOO.COM
·
2026-07-31
NEUTRAL
NEUTRAL
CORR0.35
Is Tempus AI Stock a Buy After Its CEO Sold 250,000 Shares?
$TEM
◈ ESEN AI
Tempus AI CEO executed a routine share sale of 250,000 shares under a pre-established trading plan, representing approximately 4% of his indirect holdings. The founder retained substantial equity exposure with roughly 6…
SEEKINGALPHA.COM
·
2026-07-30
NEUTRAL
NEUTRAL
CORR0.42
Tempus AI, Inc. (TEM) Q2 2026 Earnings Call Transcript
$TEM
◈ ESEN AI
Tempus AI (TEM) released Q2 2026 earnings results via earnings call transcript. The limited summary data available suggests standard quarterly reporting rather than earnings surprise or material guidance revision. Earni…
SEEKINGALPHA.COM
·
2026-07-21
HIGH
BULLISH
CORR0.72
Tempus AI Acquires Personalis: Why Both Stocks Are A Buy Now (NASDAQ:TEM)
$TEM
$PSNL
◈ ESEN AI
Tempus AI's acquisition of Personalis represents a significant consolidation play in the precision oncology diagnostics space. The deal positions TEM to capture a substantial portion of the $20B+ minimal residual diseas…
SEEKINGALPHA.COM
·
2026-07-21
HIGH
BULLISH
CORR0.72
Personalis, Inc. (PSNL) Tempus AI, Inc. - M&A Call - Slideshow (NASDAQ:PSNL) 2026-07-20
$PSNL
$TEM
◈ ESEN AI
Personalis (PSNL) and Tempus AI (TEM) announced a merger combination, representing a significant consolidation in the genomic sequencing and AI-driven precision medicine sector. The transaction combines two complementar…
FINANCE.YAHOO.COM
·
2026-07-20
NEUTRAL
BULLISH
CORR0.52
Tempus AI Bets on MRD Testing Growth With Personalis Acquisition
$TEM
◈ ESEN AI
Tempus AI announced a strategic acquisition of Personalis to consolidate leadership in minimal residual disease (MRD) testing, a high-growth oncology diagnostics segment. The deal reinforces Tempus's pivot toward precis…
FINANCE.YAHOO.COM
·
2026-07-20
HIGH
BULLISH
CORR0.72
Tempus AI to acquire cancer-monitoring firm Personalis for $1.5B
$TEM
$PNSL
◈ ESEN AI
Tempus AI's $1.5 billion acquisition of Personalis signals accelerating consolidation in the oncology diagnostics sector, where AI-powered cancer monitoring represents a high-margin, recurring-revenue opportunity. The d…
BUSINESSWIRE
·
2026-07-20
HIGH
BULLISH
CORR0.72
Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform
$TEM
$PSNL
◈ ESEN AI
Tempus AI (TEM) announced a definitive acquisition of Personalis (PSNL), a genomics-focused precision oncology company. This deal represents a strategic consolidation within the AI-driven precision medicine ecosystem, c…
SEEKINGALPHA.COM
·
2026-07-13
NEUTRAL
BULLISH
CORR0.42
Tempus AI: Building Ultimate Healthcare Data Dominance (NASDAQ:TEM)
$TEM
◈ ESEN AI
Tempus AI (TEM) is positioned as a high-growth healthcare data and analytics platform, with the headline framing it as achieving data dominance within its vertical. The bullish thesis rests on accelerating adoption of m…
SEEKINGALPHA.COM
·
2026-07-13
NEUTRAL
NEUTRAL
CORR0.35
Tempus AI: The Market Is Betting On An Inflection I Can't Yet See (NASDAQ:TEM)
$TEM
◈ ESEN AI
Tempus AI (TEM) faces a valuation disconnect between market pricing and fundamental metrics. The analyst identifies a fair value estimate near $62.55, suggesting the current market has priced in growth expectations that…
INSIDERMONKEY.COM
·
2026-07-08
LOW
NEUTRAL
CORR0.15
Freedom Capital Initiates Coverage of Tempus AI, Inc. (TEM)
$TEM
◈ ESEN AI
Tempus AI (TEM) received analyst initiation coverage from Freedom Capital with a Hold rating and a $59 price target, a routine institutional coverage event with limited immediate market implications. Analyst initiations…
SEEKINGALPHA.COM
·
2026-06-30
NEUTRAL
BULLISH
CORR0.52
Tempus AI: Buy On Diagnostics Momentum And AI Platform Expansion (NASDAQ:TEM)
$TEM
◈ ESEN AI
Tempus AI (TEM) has secured FDA approval for its xT CDx tumor-only indication, representing a clinical validation milestone that expands the addressable market for its diagnostic platform. This approval reduces prior te…
FINANCE.YAHOO.COM
·
2026-06-16
NEUTRAL
BULLISH
CORR0.52
Tempus Al, Inc. (TEM) Opens Open-Source Digital Pathology Consortium
$TEM
◈ ESEN AI
Tempus AI (TEM) announced the launch of an open-source digital pathology consortium in collaboration with Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center. This initiative targets the development of a …
FINANCE.YAHOO.COM
·
2026-06-15
NEUTRAL
BULLISH
CORR0.58
Cathie Wood buys $529.7 million of popular new stock
$ARKK
$ARKW
$TEM
$COIN
$CRWV
◈ ESEN AI
Cathie Wood's $529.7 million investment move signals continued conviction in newly public equities, reinforcing Ark Investment Management's established pattern of early-stage capital deployment. This acquisition volume …
SEEKINGALPHA.COM
·
2026-06-11
NEUTRAL
BEARISH
CORR0.42
Tempus AI: AI Precision Medicine With A Moat (NASDAQ:TEM)
$TEM
◈ ESEN AI
Tempus AI (TEM) is trading at multi-year lows despite maintaining significant competitive advantages in the precision medicine and healthcare AI space. The stock's weakness appears disconnected from fundamental assets, …
EXPLORE OTHER FILTERS